EUR 169.35
(-0.03%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 2.94 Billion EUR | -5.87% |
2022 | 3.25 Billion EUR | 7.82% |
2021 | 3.01 Billion EUR | 6.57% |
2020 | 2.83 Billion EUR | 17.9% |
2019 | 2.4 Billion EUR | 1.22% |
2018 | 2.37 Billion EUR | 5.75% |
2017 | 2.24 Billion EUR | 5.5% |
2016 | 2.12 Billion EUR | -3.89% |
2015 | 2.21 Billion EUR | 6.14% |
2014 | 2.08 Billion EUR | 8.2% |
2013 | 1.92 Billion EUR | -0.26% |
2012 | 1.93 Billion EUR | 5.98% |
2011 | 1.82 Billion EUR | 7.36% |
2010 | 1.69 Billion EUR | 60.95% |
2009 | 1.05 Billion EUR | -44.76% |
2008 | 1.91 Billion EUR | -8.0% |
2007 | 2.07 Billion EUR | 49.89% |
2006 | 1.38 Billion EUR | 1.84% |
2005 | 1.36 Billion EUR | -35.92% |
2004 | 2.12 Billion EUR | 11.05% |
2003 | 1.91 Billion EUR | 721.76% |
2002 | -307.36 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 1.61 Billion EUR | 0.0% |
2023 Q2 | 1.2 Billion EUR | 0.0% |
2023 FY | 3.06 Billion EUR | -5.87% |
2023 Q4 | 1.47 Billion EUR | 0.0% |
2022 FY | 3.25 Billion EUR | 7.82% |
2022 Q2 | 1.44 Billion EUR | 0.0% |
2022 Q4 | 1.54 Billion EUR | 0.0% |
2021 Q2 | 1.31 Billion EUR | 0.0% |
2021 FY | 3.01 Billion EUR | 6.57% |
2021 Q4 | 1.54 Billion EUR | 0.0% |
2020 FY | 2.83 Billion EUR | 17.9% |
2020 Q4 | 1.49 Billion EUR | 0.0% |
2020 Q2 | 1.23 Billion EUR | 0.0% |
2019 Q4 | 1.31 Billion EUR | 0.0% |
2019 FY | 2.4 Billion EUR | 1.22% |
2019 Q2 | 1.09 Billion EUR | 0.0% |
2018 Q2 | 1.02 Billion EUR | 0.0% |
2018 FY | 2.37 Billion EUR | 5.75% |
2017 Q4 | 1.25 Billion EUR | 0.0% |
2017 FY | 2.24 Billion EUR | 5.5% |
2017 Q2 | 991 Million EUR | 0.0% |
2016 FY | 2.12 Billion EUR | -3.89% |
2016 Q2 | 971 Million EUR | 0.0% |
2015 FY | 2.21 Billion EUR | 6.14% |
2015 Q4 | 1.26 Billion EUR | 0.0% |
2015 Q2 | 953 Million EUR | 0.0% |
2014 Q4 | 1.13 Billion EUR | 0.0% |
2014 FY | 2.08 Billion EUR | 8.2% |
2014 Q2 | 951 Million EUR | 0.0% |
2013 Q4 | 947 Million EUR | 0.0% |
2013 Q2 | 980 Million EUR | 0.0% |
2013 FY | 1.92 Billion EUR | -0.26% |
2012 Q3 | 1.75 Million EUR | 0.0% |
2012 FY | 1.93 Billion EUR | 5.98% |
2012 Q4 | 4 Million EUR | 128.57% |
2012 Q2 | 1.75 Million EUR | 0.0% |
2012 Q1 | 1.75 Million EUR | 0.0% |
2011 Q1 | 3.25 Million EUR | 0.0% |
2011 Q2 | 3.25 Million EUR | 0.0% |
2011 Q3 | 3.25 Million EUR | 0.0% |
2011 Q4 | 1.75 Million EUR | -46.15% |
2011 FY | 1.82 Billion EUR | 7.36% |
2010 Q4 | 3.25 Million EUR | 550.0% |
2010 Q2 | 500 Thousand EUR | 0.0% |
2010 Q3 | 500 Thousand EUR | 0.0% |
2010 Q1 | 500 Thousand EUR | 0.0% |
2010 FY | 1.69 Billion EUR | 60.95% |
2009 Q4 | 500 Thousand EUR | 100.34% |
2009 FY | 1.05 Billion EUR | -44.76% |
2009 Q2 | -147.25 Million EUR | 0.0% |
2009 Q3 | -147.25 Million EUR | 0.0% |
2009 Q1 | -147.25 Million EUR | 0.0% |
2008 Q3 | -3.25 Million EUR | 0.0% |
2008 FY | 1.91 Billion EUR | -8.0% |
2008 Q1 | -3.25 Million EUR | 0.0% |
2008 Q2 | -3.25 Million EUR | 0.0% |
2008 Q4 | -147.25 Million EUR | -4430.77% |
2007 Q4 | -3.25 Million EUR | 60.61% |
2007 FY | 2.07 Billion EUR | 49.89% |
2007 Q3 | -8.25 Million EUR | 0.0% |
2007 Q2 | -8.25 Million EUR | 0.0% |
2007 Q1 | -8.25 Million EUR | 0.0% |
2006 Q3 | -39.75 Million EUR | 0.0% |
2006 Q4 | -8.25 Million EUR | 79.25% |
2006 Q2 | -39.75 Million EUR | 0.0% |
2006 FY | 1.38 Billion EUR | 1.84% |
2006 Q1 | -39.75 Million EUR | 0.0% |
2005 Q4 | -39.75 Million EUR | -367.65% |
2005 FY | 1.36 Billion EUR | -35.92% |
2005 Q2 | -8.5 Million EUR | 0.0% |
2005 Q3 | -8.5 Million EUR | 0.0% |
2005 Q1 | -8.5 Million EUR | 0.0% |
2004 Q2 | 255.55 Million EUR | 0.0% |
2004 FY | 2.12 Billion EUR | 11.05% |
2004 Q1 | 255.55 Million EUR | 0.0% |
2004 Q3 | 255.55 Million EUR | 0.0% |
2004 Q4 | -8.5 Million EUR | -103.33% |
2003 Q4 | 255.55 Million EUR | -14.73% |
2003 Q3 | 299.69 Million EUR | 0.0% |
2003 Q1 | 299.69 Million EUR | 0.0% |
2003 Q2 | 299.69 Million EUR | 0.0% |
2003 FY | 1.91 Billion EUR | 721.76% |
2002 Q3 | -227.87 Million EUR | 0.0% |
2002 Q2 | -227.87 Million EUR | 0.0% |
2002 Q1 | -227.87 Million EUR | 0.0% |
2002 FY | -307.36 Million EUR | 0.0% |
2002 Q4 | 299.69 Million EUR | 231.52% |
2001 Q4 | -227.87 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -70309.402% |
ABIVAX Société Anonyme | 127.37 Million EUR | -2208.912% |
Adocia SA | 15.62 Million EUR | -18717.583% |
Aelis Farma SA | 18.81 Million EUR | -15527.823% |
Biophytis S.A. | 14.33 Million EUR | -20419.082% |
Advicenne S.A. | 8.21 Million EUR | -35700.365% |
genOway Société anonyme | 16.73 Million EUR | -17470.497% |
IntegraGen SA | 5.35 Million EUR | -54846.184% |
Medesis Pharma S.A. | 1.56 Million EUR | -187874.73% |
Neovacs S.A. | 10.34 Million EUR | -28333.192% |
NFL Biosciences SA | 4.37 Million EUR | -67132.8% |
Plant Advanced Technologies SA | 2.76 Million EUR | -106271.051% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -171090.915% |
Sensorion SA | 27.05 Million EUR | -10770.975% |
Theranexus Société Anonyme | 3 Million EUR | -97770.64% |
TME Pharma N.V. | 5.49 Million EUR | -53401.91% |
Valbiotis SA | 9.86 Million EUR | -29700.385% |
TheraVet SA | 1.64 Million EUR | -178758.891% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | -14373.425% |
argenx SE | 1.34 Billion EUR | -119.044% |
BioSenic S.A. | 7.58 Million EUR | -38684.122% |
Celyad Oncology SA | 8.49 Million EUR | -34540.754% |
DBV Technologies S.A. | 89.4 Million EUR | -3189.496% |
Galapagos NV | 327.98 Million EUR | -796.682% |
Genfit S.A. | 54.8 Million EUR | -5266.397% |
GeNeuro SA | 14.35 Million EUR | -20384.353% |
Hyloris Pharmaceuticals SA | 17.98 Million EUR | -16250.698% |
Innate Pharma S.A. | 64.57 Million EUR | -4454.747% |
Inventiva S.A. | 120.18 Million EUR | -2347.04% |
MaaT Pharma SA | 21.59 Million EUR | -13517.002% |
MedinCell S.A. | 32.92 Million EUR | -8833.236% |
Nanobiotix S.A. | 58.92 Million EUR | -4890.921% |
Onward Medical N.V. | 20.64 Million EUR | -14145.58% |
Oryzon Genomics S.A. | 18.49 Million EUR | -15799.784% |
OSE Immunotherapeutics SA | 23.58 Million EUR | -12367.676% |
Oxurion NV | 12.21 Million EUR | -23978.926% |
Pharming Group N.V. | 204.24 Million EUR | -1339.904% |
Poxel S.A. | 28.76 Million EUR | -10124.231% |
GenSight Biologics S.A. | 32.66 Million EUR | -8904.899% |
Transgene SA | 31.23 Million EUR | -9316.925% |
Financière de Tubize SA | 114.38 Thousand EUR | -2570951.412% |
Valneva SE | 134.92 Million EUR | -2079.746% |
Vivoryon Therapeutics N.V. | 24.69 Million EUR | -11810.74% |